Cypralis Ltd:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Cypralis Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11046
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:22
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥33,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥67,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥100,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Cypralis Ltd (Cypralis), formerly Selcia Pharma Ltd is a drug developer that provides discovery and development of therapeutics targeting peptidyl-prolyl isomerases. The company spans its expertise in the development of medicines for degenerative diseases such as acute tissue injury, liver disease, inflammation, and others. It develops pplases enzymes that are characterized by their ability to catalyze interconversion of cis- and trans- peptidyl-proline bonds in proteins that are able to exert control over target protein structure and functions. Cypralis works in partnership with pharma and biotech companies to develop ppiase inhibitors for acute and chronic diseases. The company operates in the UK. Cypralis is headquartered in Cambridge, the UK.

Cypralis Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Cypralis Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cypralis Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Cypralis Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Cypralis Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Cypralis Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Cypralis Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Cypralis Acquires Cyclophilin Inhibitor Assets from Scynexis 10
Partnerships 11
Cypralis Enters into Research Agreement with Janssen Pharma 11
Selcia Enters into Collaboration Agreement with Cypralis 12
Licensing Agreements 13
Cypralis Enters into Licensing Agreement with Gilead Sciences 13
Cypralis Ltd – Key Competitors 14
Cypralis Ltd – Key Employees 15
Cypralis Ltd – Locations And Subsidiaries 16
Head Office 16
Recent Developments 17
Government and Public Interest 17
Mar 07, 2017: $4 Million in New Grants Support Several First-in-class Dementia Treatments 17
Mar 01, 2017: Cypralis Announces Grant Award from Alzheimer’s Drug Discovery Foundation 20
Product News 21
03/07/2017: Alzheimer’s Drug Discovery Foundation Awards $523,940 Million for Selective Cyclophilin D Inhibitors for Neurodegeneration 21
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22

List of Tables
Cypralis Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Cypralis Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cypralis Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Cypralis Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Cypralis Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Cypralis Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Cypralis Acquires Cyclophilin Inhibitor Assets from Scynexis 10
Cypralis Enters into Research Agreement with Janssen Pharma 11
Selcia Enters into Collaboration Agreement with Cypralis 12
Cypralis Enters into Licensing Agreement with Gilead Sciences 13
Cypralis Ltd, Key Competitors 14
Cypralis Ltd, Key Employees 15

List of Figures
Cypralis Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Cypralis Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Cypralis Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Cypralis Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Cypralis Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cypralis Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Cypralis Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Cypralis Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Cypralis Ltd:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Arca Continental SAB de CV:戦略・SWOT・企業財務分析
    Arca Continental SAB de CV - Strategy, SWOT and Corporate Finance Report Summary Arca Continental SAB de CV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Kainos Medicine Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Kainos Medicine Inc (Kainos) is a drug discovery and development company that develops drugs and medicines for cancer, brain disease, metabolic and infectious diseases. The company offers antiviral drugs, Parkinson’s drugs, HIV drugs, anticancer drugs and HBV medications. Its anticancer drug …
  • Medicontur Medical Engineering Ltd:製品パイプライン分析
    Summary Medicontur Medical Engineering Ltd (Medicontur) is a developer and manufacturer of intraocular lenses. The company offers hydrophilic and hydrophobic model lenses including monofocal aspheric, toric, and standard monofocal aspheric lenses; preloaded capsular tension rings; PMMA implants; inj …
  • Nikkei Inc.:企業の戦略的SWOT分析
    Nikkei Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • American States Water Company (AWR):企業の財務・戦略的SWOT分析
    Summary American States Water Company (AWR) is a utility service provider that offers water, wastewater and electric services. The utility provides operation, construction management and maintenance services for water and wastewater systems located on military bases across the US. It offers water se …
  • Efore Oyj (EFO1V):企業の財務・戦略的SWOT分析
    Efore Oyj (EFO1V) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Elron Electronic Industries Ltd (ELRNF):医療機器:M&Aディール及び事業提携情報
    Summary Elron Electronic Industries Ltd (Elron), a subsidiary of IDB Holding Corp Ltd, is a provider of medical device and cyber technology solutions. The company offers development of patient care systems for stroke care, microbiology, age-related macular degeneration, orthopedics, and heart diseas …
  • Stanmore Coal Ltd:企業の戦略・SWOT・財務分析
    Stanmore Coal Ltd - Strategy, SWOT and Corporate Finance Report Summary Stanmore Coal Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • eFFECTOR Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary eFFECTOR Therapeutics Inc (eFFECTOR) is a clinical-stage biopharmaceutical company that focuses on the discovery and development of selective translation regulators for the treatment of cancer. Its investigational compounds are designed to restore the translational control of processes that …
  • The Boeing Co (BA):企業の財務・戦略的SWOT分析
    The Boeing Co (BA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Volkswagen AG:企業の戦略・SWOT・財務分析
    Volkswagen AG - Strategy, SWOT and Corporate Finance Report Summary Volkswagen AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Navigant Consulting Inc (NCI):企業の財務・戦略的SWOT分析
    Summary Navigant Consulting Inc (Navigant Consulting) is a consultancy service provider that provides integrated solutions to assist companies and legal counsel in improving stakeholder value and operations. The company offers growth strategy, operations and transaction advisory services such as str …
  • Cytori Therapeutics Inc (CYTX)-医療機器分野:企業M&A・提携分析
    Summary Cytori Therapeutics Inc (Cytori) is a clinical stage regenerative medicine company. It develops cell therapies based on autologous adipose-derived regenerative cells (ADRCs) for the treatment of cardiovascular disease, orthopedic conditions and gastrointestinal disorders. The company has two …
  • PanOptica Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary PanOptica Inc (PanOptica) is a clinical-stage biopharmaceutical company that develops topical eye drops for the treatment of sight-threatening eye diseases. The company concentrates on candidates that are at or near the investigational new drug application stage. It develops PAN-90806, a nov …
  • SymBio Pharmaceuticals Ltd (4582):企業の財務・戦略的SWOT分析
    Summary SymBio Pharmaceuticals Ltd (SymBio) is a biopharmaceutical company that develops and markets anti-cancer drug candidates. Its pipeline product portfolio includes Treakisym (SyB L-0501), an anti-cancer agent used for the treatment of non-Hodgkin's lymphoma (NHL), multiple myeloma (MM) and chr …
  • Battalion Oil Corp (HKRSQ):企業の財務・戦略的SWOT分析
    Summary Battalion Oil Corp (Battalion Oil), formerly Halcon Resources Corp, is an independent energy company that carries out the acquisition, production, exploration and development of onshore oil and natural gas properties. Battalion Oil mainly focuses on the Delaware Basin, East Texas. The compan …
  • Proteus Digital Health Inc:企業の戦略的SWOT分析
    Proteus Digital Health Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Wellcome Trust Sanger Institute-医療機器分野:企業M&A・提携分析
    Summary Wellcome Trust Sanger Institute (Sanger Institute), a subsidiary of Genome Research Ltd is a genomic discovery and research centre that carries out research and development in the areas of cellular and human genetics and infection genomics. It also provides postgraduate training on research …
  • Midatech Pharma Plc (MTPH):企業の財務・戦略的SWOT分析
    Summary Midatech Pharma Plc (Midatech) is a pharmaceutical company that develops and commercializes products in oncology and other therapeutic areas. The company’s products include gelclair, oravig, soltamox and zuplenz. It conducts research and development programs in the areas of oncology, autoimm …
  • Purity Wholesale Grocers Inc:企業の戦略的SWOT分析
    Purity Wholesale Grocers Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆